This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jian Cui, MD, PhD; Jean-Claude Bystryn, MD

Arch Dermatol. 1995;131(3):314-318.

Abstract
Background and Design
Several clinical observations suggest that there is a link between vitiligo and melanoma. We examined whether an immune response to similar antigens on pigment cells could account for this association. We tested 30 patients with melanoma, 29 patients with vitiligo, and 28 patients with unrelated conditions for antibodies to human melanocyte antigens using an immunoprecipitation sodium dodecyl sulfate— polyacrylamide gel electrophoresis (SDS-PAGE) analysis assay.

Results
Antibodies to melanocytes were present in 24 (80%) patients from the melanoma group, 24 (83%) patients from the vitiligo group, and in two (7%) patients from the control group. The antibodies in patients with melanoma or vitiligo were directed to similar antigens with molecular weights of approximately 40 to 45, 75, and 90 kd. The frequency of antibody responses to each of these antigens was similar in both diseases. By sequential immunodepletion, the antigens defined by antibodies in both diseases were similar. These antigens were also expressed on melanoma cells.

Conclusions
Most patients with melanoma or with vitiligo develop antibodies to similar antigens that are present both on melanocytes and on melanoma cells. These findings support the hypothesis that the clinical link between the two diseases results from immune responses to antigens shared by normal and malignant pigment cells.

(Arch Dermatol. 1995;131:314-318)

Author Affiliations
From The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
Quaglino et al.
Ann Oncol 2010;21:409-414.
ABSTRACT | FULL TEXT  

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: Comparison of Prophylaxis and Therapy
van Elsas et al.
JEM 2001;194:481-490.
ABSTRACT | FULL TEXT  

Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma: Direct Evidence of T Cell-Mediated Vitiligo
Yee et al.
JEM 2000;192:1637-1644.
ABSTRACT | FULL TEXT  

Fc receptors are required in passive and active immunity to melanoma
Clynes et al.
Proc. Natl. Acad. Sci. USA 1998;95:652-656.
ABSTRACT | FULL TEXT